Back to top

Image: Bigstock

Glaxo (GSK), SK bioscience's COVID-19 Jab Enters Phase III Study

Read MoreHide Full Article

GlaxoSmithKline plc (GSK - Free Report) , along with Korean biopharmaceutical company SK bioscience, announced that they have initiated a phase III study on the latter’s nanoparticle COVID-19 vaccine candidate, GBP510, which is being developed using Glaxo’s pandemic adjuvant.

The randomized phase III study will evaluate the safety and immunogenicity of GBP510 as compared to an active comparator – the Oxford University and AstraZeneca’s (AZN - Free Report) COVID-19 vaccine. The study will enroll approximately 4,000 participants from various countries, and is likely to be one of the first phase III studies to compare different COVID-19 vaccine candidates.

Data from the above-mentioned study is expected in the first half of 2022. If successfully developed and upon potential approval, the vaccine is expected to be supplied at scale through the COVAX facility across the globe.

Glaxo and SK bioscience decided to advance the vaccine candidate to the phase III study after interim data from the phase I/II study showed that all participants who received the adjuvanted vaccine candidate developed strong neutralizing antibody responses with a 100% seroconversion rate.

Shares of Glaxo have increased 10.7% so far this year compared with the industry’s growth of 16.2%.

Zacks Investment Research
Image Source: Zacks Investment Research

We note that Glaxo entered into multiple partnerships with various companies like Sanofi (SNY - Free Report) , Medicago, SK Biosciences and others to help make their COVID-19 vaccine candidates in combination with Glaxo’s pandemic adjuvant. Sanofi’s adjuvanted COVID-19 vaccine candidate is currently in phase III development. Glaxo also has a partnership with German biopharmaceutical company CureVac N.V. (CVAC - Free Report) to develop the next-generation mRNA COVID vaccines.

In the second quarter of 2021, Glaxo recorded sales of £260 million from its pandemic vaccines, including £258 million of pandemic adjuvant sales. Potential approval for COVID-19 vaccines should boost sales further in future quarter.

Other than vaccines, Glaxo is also making therapies for COVID-19. In May 2021, the FDA granted an emergency use authorization to Glaxo and Vir Biotechnology, Inc.’s sotrovimab, an investigational single-dose monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients. Sotrovimab is currently under review in the EU.

Zacks Rank

Glaxo currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Sanofi (SNY) - free report >>

AstraZeneca PLC (AZN) - free report >>

GlaxoSmithKline plc (GSK) - free report >>

CureVac N.V. (CVAC) - free report >>